SLC12A5 and nervous system disorder: Moreover, the development of additional clinical biomarkers of KCC2 hypofunction and pharmacodynamic biomarkers of KCC2 potentiation therapy will enable further indication selection and patient stratification to realize the full potential of these therapeutics to address CNS disinhibition and drug-resistance in neurological disorder patients with unmet needs, likely providing a more tolerable and precise medication to address their chronic pathologies.